NZ602625A - Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and a nmda-antagonist for the treatment of pain - Google Patents

Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and a nmda-antagonist for the treatment of pain

Info

Publication number
NZ602625A
NZ602625A NZ602625A NZ60262511A NZ602625A NZ 602625 A NZ602625 A NZ 602625A NZ 602625 A NZ602625 A NZ 602625A NZ 60262511 A NZ60262511 A NZ 60262511A NZ 602625 A NZ602625 A NZ 602625A
Authority
NZ
New Zealand
Prior art keywords
pain
nmda
dimethylamino
phenol
propyl
Prior art date
Application number
NZ602625A
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ602625(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of NZ602625A publication Critical patent/NZ602625A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ602625A 2010-06-15 2011-06-14 Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and a nmda-antagonist for the treatment of pain NZ602625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15
PCT/EP2011/002905 WO2011157391A1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain

Publications (1)

Publication Number Publication Date
NZ602625A true NZ602625A (en) 2014-03-28

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602625A NZ602625A (en) 2010-06-15 2011-06-14 Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and a nmda-antagonist for the treatment of pain

Country Status (29)

Country Link
US (3) US8846765B2 (enExample)
EP (2) EP2582366B1 (enExample)
JP (3) JP6133772B2 (enExample)
KR (1) KR101831616B1 (enExample)
CN (1) CN103108631B (enExample)
AR (1) AR081931A1 (enExample)
AU (2) AU2011267474B2 (enExample)
BR (1) BR112012031836A2 (enExample)
CA (1) CA2796774C (enExample)
CL (1) CL2012002551A1 (enExample)
CO (1) CO6602157A2 (enExample)
CY (1) CY1117118T1 (enExample)
DK (1) DK2582366T3 (enExample)
EC (2) ECSP12012217A (enExample)
ES (1) ES2560676T3 (enExample)
HK (1) HK1215787A1 (enExample)
HR (1) HRP20151327T1 (enExample)
HU (1) HUE026619T2 (enExample)
IL (1) IL221926A (enExample)
MX (1) MX2012014482A (enExample)
NZ (1) NZ602625A (enExample)
PE (2) PE20130243A1 (enExample)
PL (1) PL2582366T3 (enExample)
PT (1) PT2582366E (enExample)
RS (1) RS54439B1 (enExample)
RU (2) RU2589692C2 (enExample)
SI (1) SI2582366T1 (enExample)
WO (1) WO2011157391A1 (enExample)
ZA (1) ZA201208646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
PE20141906A1 (es) * 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CA3128321C (en) 2013-01-22 2023-12-05 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3636251B1 (en) 2013-03-15 2022-01-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
US20170072005A1 (en) * 2014-05-06 2017-03-16 Northwestern University Combinations of nmdar modulating compounds
MX2017001908A (es) 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Metodo para el tratamiento de la depresion.
WO2016044150A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019126108A1 (en) 2017-12-22 2019-06-27 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
CA3096671C (en) 2018-04-12 2025-09-16 Anavex Life Sciences Corp. CRYSTALLINE POLYMORPHIC COMPOSITIONS A2-73 OF MATERIAL AND THEIR METHODS OF USE
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
KR100762018B1 (ko) * 1998-07-16 2007-10-04 메모리얼 슬로안-케터링 캔서 센터 오피오이드 진통제 및 엔엠디에이 길항제를 함유하는 국소조성물
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
JP2006500395A (ja) * 2002-09-09 2006-01-05 エンド ファーマシューティカルズ インコーポレーテッド 組み合わされた即時放出及び徐放の鎮痛組成物
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
MX2008013828A (es) 2006-04-28 2008-11-10 Gruenenthal Gmbh Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
EP2012764B1 (en) 2006-04-28 2011-01-12 Grünenthal GmbH Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
CA2652667A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
WO2009067703A2 (en) * 2007-11-23 2009-05-28 Nectid, Inc. Tapentadol compositions
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
LT2735338T (lt) * 2008-09-05 2019-04-10 Grünenthal GmbH 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
SG188300A1 (en) 2010-09-21 2013-04-30 Purdue Pharma Lp Buprenorphine analogs
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
EA028149B1 (ru) 2011-03-04 2017-10-31 Грюненталь Гмбх Парентеральное введение тапентадола
CA2868413C (en) 2012-04-17 2021-07-20 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Also Published As

Publication number Publication date
JP6133772B2 (ja) 2017-05-24
US10813890B2 (en) 2020-10-27
AU2011267474A1 (en) 2013-01-10
ES2560676T3 (es) 2016-02-22
JP6197007B2 (ja) 2017-09-13
JP2017141277A (ja) 2017-08-17
CN103108631A (zh) 2013-05-15
US20140309311A1 (en) 2014-10-16
CO6602157A2 (es) 2013-01-18
BR112012031836A2 (pt) 2016-11-08
ECSP12012217A (es) 2012-11-30
CA2796774C (en) 2020-06-02
RU2013101515A (ru) 2014-07-20
HK1184370A1 (zh) 2014-01-24
AR081931A1 (es) 2012-10-31
SI2582366T1 (sl) 2016-02-29
CN103108631B (zh) 2015-08-26
EP2582366B1 (en) 2015-10-28
PE20130243A1 (es) 2013-03-22
PT2582366E (pt) 2016-01-26
RU2016119041A (ru) 2017-11-20
RU2589692C2 (ru) 2016-07-10
KR101831616B1 (ko) 2018-04-04
JP2013528629A (ja) 2013-07-11
ZA201208646B (en) 2013-09-25
AU2016219643A1 (en) 2016-09-15
HRP20151327T1 (hr) 2016-01-01
WO2011157391A1 (en) 2011-12-22
HK1215787A1 (en) 2016-09-15
CY1117118T1 (el) 2017-04-05
US20170333369A1 (en) 2017-11-23
IL221926A (en) 2015-08-31
EP2992877A1 (en) 2016-03-09
MX2012014482A (es) 2013-02-21
PL2582366T3 (pl) 2016-04-29
AU2016219643B2 (en) 2018-04-12
HUE026619T2 (en) 2016-06-28
PE20160531A1 (es) 2016-06-05
JP6423036B2 (ja) 2018-11-14
US20110306674A1 (en) 2011-12-15
US8846765B2 (en) 2014-09-30
JP2015232015A (ja) 2015-12-24
EP2582366A1 (en) 2013-04-24
CL2012002551A1 (es) 2012-11-09
KR20130111945A (ko) 2013-10-11
RU2675261C2 (ru) 2018-12-18
AU2011267474B2 (en) 2016-05-26
ECSP19047259A (es) 2019-07-31
RS54439B1 (sr) 2016-06-30
DK2582366T3 (en) 2015-12-07
CA2796774A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
NZ602625A (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and a nmda-antagonist for the treatment of pain
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
MX373763B (es) Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
EP2067765A3 (en) Intermediate compounds and their use in preparation of lacosamide
MX342609B (es) Conjugados de molecula pequeña para suministro intracelular de acidos nucleicos.
MY148948A (en) Catecholamine derivatives and prodrugs thereof
UA96076C2 (en) Use of trans-clomiphene
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
EP4494702A3 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
PH12013500695A1 (en) Pharmaceutical compositions containing a dgat1 inhibitor
EP3133073A3 (en) Inhibitors of iap
NZ593524A (en) A nonapeptide with anti-tumour activity
MX360330B (es) Regimen de administracion para nitrocatecoles.
EP2597518A3 (en) Compositions and antireflective coatings for photolithography
CA2767833C (en) N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
JP2011529069A5 (enExample)
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX346980B (es) Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona.
TW200745122A (en) New compounds I
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof
MX2011008876A (es) Metabolitos analogos de ceramida.
WO2011121607A3 (en) Rasagiline and its pharmaceutically acceptable salts
MY170616A (en) Skin cleansing composition
RU2011112443A (ru) Фармацевтическая комбинация, которая содержит 6-диметиламинометил-1-(3-метокси-фенил)-циклогексан-1,3-диол и парацетамол

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2016 BY CPA GLOBAL

Effective date: 20150501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2017 BY CPA GLOBAL

Effective date: 20160429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2018 BY CPA GLOBAL

Effective date: 20170428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2019 BY CPA GLOBAL

Effective date: 20180503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2020 BY CPA GLOBAL

Effective date: 20190502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2021 BY CPA GLOBAL

Effective date: 20200430

LAPS Patent lapsed